Modulatory Effects of Structurally Characterized Medicinal Plants on Oxidative Stress, Neuroinflammation, and Apoptotic Pathways in Preclinical Rodent Models of Cerebral Ischemia: A Rapid Narrative Review Protocol

This rapid narrative review aims to systematically search, extract, and synthesize preclinical evidence evaluating how structurally characterized medicinal plants and their isolated phytoconstituents modulate specific downstream pathological cascades following cerebral ischemia. The study design is strictly guided by a preclinical PICO framework. The Population (P) is limited to in vivo rodent models of cerebral ischemia (specifically Rattus norvegicus and Mus musculus strains). The Intervention (I) encompasses crude or fractionated extracts of medicinal plants, or their isolated phytoconstituents, which must possess clear extraction solvent data and explicit mass-concentration dosing metrics (mg/kg). The Comparison (C) group comprises vehicle-treated ischemic controls and sham-operated animal cohorts. The primary Outcomes (O) of interest include quantitative changes and directional vectors across six locked molecular benchmarks: Superoxide Dismutase (SOD) and Malondialdehyde (MDA) for oxidative stress; Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6) for neuroinflammation; and Caspase-3 and B-cell lymphoma 2 (Bcl-2) for apoptotic cascades. Macroscopic phenotypes, including percentage infarct volume reduction via TTC staining and neurological deficit behavioral scores, serve as secondary outcomes. To facilitate a high-velocity synthesis, electronic literature searches will be restricted to two primary biomedical databases: PubMed and Europe PMC, covering a focused 10-year publication window from January 1, 2016, to 31st October 2026. The search architecture applies boolean logic targeting title and abstract fields using targeted wildcard string terms such as "cerebral ischemia", "ischemic stroke", "plant extract*", "phytochemical*", "neuroinflammation", and "apoptosis". Studies will be independently screened in duplicate by two team members, with conflicts resolved by a third referee. Studies will be excluded immediately and logged under specific screening error codes if they utilize in vitro models exclusively [NOT_RODENT], evaluate non-ischemic neurological injury modes [NOT_ISCHEMIA], or completely omit quantitative endpoint reporting for the target biomarkers [NO_MOLECULAR_DATA]. Additionally, strict pharmacological quality gates will be applied; any full-text paper that fails to report the anatomical plant part used, the specific extraction solvent utilized, or the exact operational dosage regimen will be systematically purged from the final data repository to ensure ethnopharmacological reproducibility. Data extraction will be managed uniformly via a collaborative, synchronized master matrix tracking 22 explicit study variables across metadata, botanical taxonomy, surgical design parameters, and directional outcome vectors. Botanical nomenclature will be checked and verified against the World Flora Online database to enforce authoritative Latin binomials and family designations. Methodological quality and internal risk of bias for all included in vivo studies will be independently appraised using the 10 structural signaling domains of the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) tool, spanning selection, performance, detection, attrition, and reporting bias criteria. Because this is a rapid review, findings will not be pooled in a meta-analysis; instead, a narrative synthesis will be conducted. Interventions will be categorized conceptually by major phytochemical compound classes (e.g., flavonoids, polyphenols, terpenoids) rather than listed lineally by publication, mapping their mechanistical interactions with downstream microglial suppression, NF-κB pathways, and mitochondrial cell-survival signaling to deliver a robust, publication-grade overview.